Abstract | UNLABELLED: A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. PATIENT SUMMARY:
|
Authors | Andrea Gallina, Marco Bianchi, Giorgio Gandaglia, Vito Cucchiara, Nazareno Suardi, Francesco Montorsi, Alberto Briganti |
Journal | European urology
(Eur Urol)
Vol. 68
Issue 5
Pg. 750-3
(Nov 2015)
ISSN: 1873-7560 [Electronic] Switzerland |
PMID | 25700565
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Phosphodiesterase 5 Inhibitors
- KLK3 protein, human
- Kallikreins
- Prostate-Specific Antigen
|
Topics |
- Aged
- Erectile Dysfunction
(drug therapy)
- Humans
- Kallikreins
(blood)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(blood, epidemiology)
- Phosphodiesterase 5 Inhibitors
(therapeutic use)
- Postoperative Complications
(drug therapy)
- Proportional Hazards Models
- Prostate-Specific Antigen
(blood)
- Prostatectomy
- Prostatic Neoplasms
(blood, surgery)
- Risk Factors
|